NANOVIRICIDES, INC.

NanoViricides is a clinical-stage biopharmaceutical company focused on developing antiviral treatments using nanoparticle technology. The company's primary development program centers on NV-387, a drug candidate in Phase 1a/1b trials designed to treat respiratory viral infections including RSV, influenza, and COVID-19. NV-387 is being developed in multiple formulations: oral syrup and gummies for pediatric COVID treatment, injectable solution for moderate cases, and inhalation solution via nebulizer for severe respiratory infections. The company is also advancing NV-HHV-1 for herpesvirus infections, with a skin cream formulation completed in non-clinical studies and oral formulations in development for cold sores and genital herpes. Additional programs include HIVCide candidates targeting dengue and Ebola virus.

The company operates primarily through its proprietary nanoviricide platform technology, which forms the basis for its drug development pipeline. As a clinical-stage enterprise, NanoViricides does not currently generate product revenue, instead relying on development funding to advance its candidates through human trials.

Based in Shelton, Connecticut, NanoViricides operates with a small team of seven full-time employees. The company is incorporated in Delaware and trades on the New York Stock Exchange.